Dear LBank users,
LBank ETF will launch GOATSEUS and BOME at 09:00 on November 7, 2024 (UTC) with 3x leverage.
More details can be found in the table below:
| Token | 3X Buy (Long) | 3X Sell (Short) |
| GOATSEUS |
GOATSEUS3L/USDT |
GOATSEUS3S/USDT |
| BOME | BOME3L/USDT | BOME3S/USDT |
※ "3L" means 3x buy long, "3S" means 3x sell short.
Risk Warning:
Welcome to trade LBank ETF products, where you can easily amplify your profits by taking long or short positions.
-
Leveraged ETF products are newly emerged financial derivatives. LBank will not provide any financial advice regarding to leveraged ETF trading. Please make prudent investment decisions.
-
Leveraged ETFs greatly reduce the risk of forced liquidation, but there is a risk of approaching zero and liquidation in extreme market conditions. Please pay attention to the difference between the net asset value and the price to avoid losses.
-
A management fee of 0.1% will be charged.
More Details: Guide for Leveraged ETF
LBank Community
For any assistance, please contact us at our official email service@lbank.com. We are dedicated to providing quality, professional and prompt support.
Disclaimer: Digital assets are subject to high market risks and price volatility. The value of your investments may fluctuate, and could even lead to a loss of principal. You are solely responsible for your investment decisions, and LBank is not liable for any losses you may incur. You should invest only in products you are familiar with and understand the risks involved. You should carefully consider your investment experience, financial status, investment objectives, and risk tolerance, and consult an independent financial advisor before any investment. Past performance is not a reliable indicator of future performance. Content on the LBank platform does not include advice or recommendations, and should not be construed as financial advice.
LBank reserves the right in its sole discretion to amend or cancel this announcement at any time and for any reasons without prior notice.
Comments
0 comments
Article is closed for comments.